ARCUS BIOSCIENCES INC's ticker is RCUS and the CUSIP is 03969F109. A total of 148 filers reported holding ARCUS BIOSCIENCES INC in Q4 2021. The put-call ratio across all filers is 1.22 and the average weighting 0.5%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $242,864 | -2.8% | 13,530 | +10.0% | 0.00% | 0.0% |
| Q2 2023 | $249,894 | +8.8% | 12,304 | -2.3% | 0.00% | 0.0% |
| Q1 2023 | $229,605 | -9.1% | 12,588 | +3.0% | 0.00% | 0.0% |
| Q4 2022 | $252,648 | -17.4% | 12,217 | +4.5% | 0.00% | -33.3% |
| Q3 2022 | $306,000 | +4.4% | 11,694 | +1.2% | 0.00% | 0.0% |
| Q2 2022 | $293,000 | -11.2% | 11,555 | +10.6% | 0.00% | 0.0% |
| Q1 2022 | $330,000 | -22.9% | 10,444 | -1.2% | 0.00% | 0.0% |
| Q4 2021 | $428,000 | +15.4% | 10,569 | -0.6% | 0.00% | 0.0% |
| Q3 2021 | $371,000 | +27.5% | 10,636 | +0.4% | 0.00% | +50.0% |
| Q2 2021 | $291,000 | -15.7% | 10,596 | -13.7% | 0.00% | -33.3% |
| Q1 2021 | $345,000 | +8.5% | 12,285 | +0.4% | 0.00% | 0.0% |
| Q4 2020 | $318,000 | +66.5% | 12,235 | +9.7% | 0.00% | +50.0% |
| Q3 2020 | $191,000 | -7.3% | 11,151 | +33.8% | 0.00% | -33.3% |
| Q2 2020 | $206,000 | – | 8,337 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Invus Financial Advisors, LLC | 1,612,077 | $28,936,782 | 18.14% |
| Octagon Capital Advisors LP | 1,968,000 | $35,325,600 | 5.43% |
| Decheng Capital Management III (Cayman), LLC | 869,790 | $15,612,731 | 5.21% |
| Boxer Capital, LLC | 1,602,200 | $28,759,490 | 1.53% |
| SECTORAL ASSET MANAGEMENT INC | 375,456 | $6,739,435 | 1.31% |
| DAFNA Capital Management LLC | 222,717 | $3,997,770 | 1.24% |
| PFM Health Sciences, LP | 1,405,056 | $25,220,755 | 1.19% |
| Ikarian Capital, LLC | 4,000 | $7,180,000 | 0.86% |
| Capital Impact Advisors, LLC | 24,280 | $435,826 | 0.73% |
| Parkman Healthcare Partners LLC | 205,109 | $3,681,707 | 0.68% |